Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Equity Average (2016 - 2025)

Historic Equity Average for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $35.4 million.

  • Akebia Therapeutics' Equity Average rose 18414.85% to $35.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.4 million, marking a year-over-year increase of 18414.85%. This contributed to the annual value of -$39.9 million for FY2024, which is 21462.1% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Equity Average of $35.4 million as of Q3 2025, which was up 18414.85% from $26.9 million recorded in Q2 2025.
  • Akebia Therapeutics' Equity Average's 5-year high stood at $229.1 million during Q1 2021, with a 5-year trough of -$772.9 million in Q4 2022.
  • For the 5-year period, Akebia Therapeutics' Equity Average averaged around -$49.7 million, with its median value being -$12.3 million (2025).
  • Per our database at Business Quant, Akebia Therapeutics' Equity Average crashed by 83202.29% in 2022 and then soared by 18818.76% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Equity Average (Quarter) stood at $105.6 million in 2021, then tumbled by 832.02% to -$772.9 million in 2022, then soared by 95.47% to -$35.0 million in 2023, then tumbled by 42.25% to -$49.8 million in 2024, then soared by 171.11% to $35.4 million in 2025.
  • Its last three reported values are $35.4 million in Q3 2025, $26.9 million for Q2 2025, and -$12.3 million during Q1 2025.